Corium is a commercial-stage biopharmaceutical company that is leading the development and commercialization of CNS healthcare therapies that provide clinicians with important treatment options for patients, their families, and their caregivers. Learn more at Corium.com.
AZSTARYS is now available as the first and only d-MPH with novel SDX prodrug and IR activity for the treatment of ADHD in patients 6 years and older.(1-3)
AZSTARYS provides a novel approach to symptom coverage throughout the day.(1,2) The unique, once-daily capsule contains 30% IR d-MPH for rapid absorption and 70% novel SDX prodrug designed for continuous conversion to d-MPH.(1-5) Copay savings and support are available for eligible patients prescribed AZSTARYS.
Chat with a live representative within this exhibit, or visit AZSTARYS-pro.com, to learn more.
Please see Full Prescribing Information, including Boxed WARNING, available by clicking on the Brochure button below or by visiting AZSTARYS-pro.com.
CNS, central nervous system; d-MPH, dexmethylphenidate; IR, immediate-release; SDX, serdexmethylphenidate.
References: 1. AZSTARYS. Prescribing information. Corium Inc; 2021. 2. Mickle T, Guenther S, Chi G, inventors; KemPharm, Inc, assignee. Methylphenidate-prodrugs, processes of making and using the same. U.S. patent 10,584,113. March 10, 2020. 3. Childress AC, Komolova M, Sallee FR. An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations. Expert Opin Drug Metab Toxicol. 2019;15(11):937-974. doi:10.1080/17425255.2019.1675636 4. Patrick KS, Radke JL, Raymond JR, et al. Drug regimen individualization for attention-deficit/hyperactivity disorder: guidance for methylphenidate and dexmethylphenidate formulations. Pharmacotherapy. 2019;39(6):677-688. doi:10.1002/phar.2190 5. Gudin JA, Nalamachu SR. An overview of prodrug technology and its application for developing abuse-deterrent opioids. Postgrad Med. 2016;128(1):97-105. doi:10.1080/00325481.2016.1126186